Compositions for regulating the autonomic nervous system

Abstract

This specification provides compositions for use in regulating the autonomic nervous system.

Description

Technical Field

[0001] The present invention relates to a composition for use in regulating the autonomic nervous system.

Background Art

[0002] The human autonomic nervous system is part of the peripheral nervous system and contributes to maintaining homeostasis by regulating various involuntary physiological processes. The autonomic nervous system regulates functions such as cardiac function, involuntary respiration, hormone secretion, body temperature, blood flow and blood pressure, digestion, and metabolism. The autonomic nervous system plays a role in most physiological systems, such as the cardiovascular system or the gastrointestinal tract system. Therefore, the regulation of the autonomic nervous system is related to several conditions. In particular, the regulation of the autonomic nervous system plays a role in the treatment of respiratory problems and thermoregulation.

[0003] Thermoregulation is a mechanism that maintains the body temperature constant at a physiological temperature. In humans, the body temperature depends on the location where it is measured and varies throughout the day. Nevertheless, the physiological body temperature of humans is considered to be approximately 37°C. However, under certain conditions, humans can experience an increase or decrease in body temperature, which results in symptoms such as feeling too hot or too cold, fever, night sweats, tremors, etc. Hormonal changes are a major factor in thermoregulation and in the symptoms of feeling too hot or too cold. For example, human subjects with disrupted hormone balance (such as women in the perimenopausal / menopausal period) and human subjects receiving hormone therapy can have a disrupted thermoregulatory balance. These individuals would greatly benefit from treatment for regulating the autonomic nervous system, particularly for improving thermoregulation.

[0004] U.S. Patent Application Publication No. 2012 / 015882 discloses an orally ingestible composition for regulating autonomic activity. This composition contains the peptide Tyr-Pro or a salt thereof as an active ingredient.

[0005] European Patent Application Publication No. 2143719 discloses a pharmaceutical composition, food, or beverage containing 2,3-dihydro-3,5-dihydroxy-6-methyl-4H-pyran-4-one, which has an autonomic nervous system regulating effect.

[0006] Conventional technologies generally focus on pharmaceutical synthetic components that are costly to produce. In this field, there is still a need for nutritional compositions that can be taken with a subject's normal diet and that can regulate the autonomic nervous system. [Overview of the project] [Means for solving the problem]

[0007] The inventors have surprisingly discovered that a composition containing a combination of gamma-aminobutyric acid (GABA) and jujube improves autonomic nervous system regulation in human subjects. More specifically, the combination of GABA and jujube improved thermoregulation (bidirectional) and respiration in human subjects. Improved respiration also resulted in reduced snoring in these subjects.

[0008] Through clinical studies and investigations, the inventors have surprisingly discovered that the compositions of the present invention exhibit considerable benefits in regulating the autonomic nervous system. These benefits are thought to result in positive effects in the treatment and / or prevention of one or more of the following conditions: hyperlipidemia, hypertension, diabetes, obesity, overweight, stress, anxiety, depression, and memory loss.

[0009] Gamma-aminobutyric acid (GABA) is an inhibitory neurotransmitter that reduces the excitability of nerve cells. While we do not wish to be bound by theory, the inventors believe that jujube fruit enhances the inhibitory effect of GABA.

[0010] Therefore, the present invention relates to the production of a composition for regulating the autonomic nervous system in human subjects, (i) γ-aminobutyric acid, (ii) Jujube Regarding the combination use of [these terms].

[0011] The present invention relates to the manufacture of a composition for treating and / or preventing one or more stress, anxiety, depression, and memory loss in human subjects. (i) γ-aminobutyric acid, (ii) Jujube Further details on the use of combinations of these.

[0012] Finally, the present invention relates to a scoring method for regulating the autonomic nervous system in human subjects, (i) γ-aminobutyric acid, (ii) Jujube The method involves administering a composition containing the above to a human subject on a daily basis. a. Steps to obtain user information from human subjects, b. A step to obtain a happiness level analysis by analyzing the obtained user information. c. Based on the results of the happiness analysis, • A step of providing a happiness score to human subjects, and / or • A step of providing one or more suggestions for behavioral change to human subjects. The present invention further includes applying a happiness scoring system having a scoring method, wherein steps a. to c. are repeated at least daily. [Modes for carrying out the invention]

[0013] Therefore, a first aspect of the present invention relates to the production of a composition for regulating the autonomic nervous system in a human subject, (i) γ-aminobutyric acid, (ii) Jujube Regarding the combination use of [these terms].

[0014] In some jurisdictions, the present invention is intended for use in regulating the autonomic nervous system in human subjects. (i) γ-aminobutyric acid, (ii) Jujube It can also be expressed as a composition containing [the specified element].

[0015] In some other jurisdictions, the present invention is a method for regulating the autonomic nervous system in a human subject, comprising (i) gamma-aminobutyric acid, (ii) jujube and may also be expressed as a method comprising administering to the human subject a composition comprising the same.

[0016] In some jurisdictions, "regulating the autonomic nervous system" may be considered non-therapeutic. By definition, the term "non-therapeutic" excludes any therapeutic effect. Thus, in some jurisdictions, the present invention is a non-therapeutic method for regulating the autonomic nervous system in a human subject, comprising (i) gamma-aminobutyric acid, (ii) jujube and may also be expressed as a method comprising administering to the human subject a composition comprising the same.

[0017] A second aspect of the present invention relates to the use of a combination of (i) gamma-aminobutyric acid, (ii) jujube in the manufacture of a composition for treating and / or preventing one or more of hyperlipidemia, hypertension, diabetes, obesity, overweight, stress, anxiety, depression and memory loss in a human subject, preferably for treating and / or preventing one or more of stress, anxiety, depression and memory loss in a human subject.

[0018] In some jurisdictions, a second aspect of the present invention is for use in the treatment and / or prevention of one or more of hyperlipidemia, hypertension, diabetes, obesity, overweight, stress, anxiety, depression and memory loss in a human subject, preferably for the treatment and / or prevention of one or more of stress, anxiety, depression and memory loss in a human subject, (i) gamma-aminobutyric acid, (ii) jujube and may also be expressed as a composition comprising the same.

[0019] In some other jurisdictions, a second aspect of the present invention is a (non-therapeutic) method for treating and / or preventing one or more of the following conditions in a human subject: hyperlipidemia, hypertension, diabetes, obesity, overweight, stress, anxiety, depression and memory loss. (i) γ-aminobutyric acid, (ii) Jujube This can also be expressed as a method comprising administering a composition containing to a human subject.

[0020] In relation to the present invention, the following definitions are provided.

[0021] As used herein, the term "jujube" refers to the plant jujube (Ziziphus jujuba), also known as Chinese dates, spine dates, spina dates, or red dates. As used herein, the term "jujube" encompasses any part of the plant, fruit, leaves, seeds, or extracts, unless otherwise specified. Jujube seeds are also known as sour jujube seeds.

[0022] As used herein, the term "thermoregulation" refers to the ability of an organism to maintain its internal body temperature at approximately a constant physiological temperature. In humans, body temperature is location-dependent and fluctuates throughout the day. The physiological internal body temperature of humans is considered to be 37°C ± 1°C. As used herein, bidirectional thermoregulation refers to the ability to maintain internal body temperature either above (too high) or below (too low) 37°C.

[0023] As used herein, the term "lipid" includes one or more selected from the group consisting of triglycerides, free fatty acids, monoglycerides and diglycerides, and polar lipids. The terms "lipid," "fat," and "oil" are used interchangeably herein and have the same meaning.

[0024] Preferably, the human subjects are at least 30 years old, more preferably at least 40 years old, and most preferably at least 50 years old.

[0025] In one preferred embodiment, regulating the autonomic nervous system in a human subject is to improve thermoregulation. As used herein, “improving thermoregulation” preferably includes lowering, maintaining, and raising body temperature to approximately physiological body temperature. Improving thermoregulation preferably includes treating one or more symptoms selected from feeling too hot, feeling too cold, dry mouth, miliaria, excessive sweating, goosebumps, night sweats, and hot flashes. Preferably, the human subject is one or more of the following: a hormonally imbalanced human subject, a human subject receiving hormone therapy, a low-weight human subject, a high-weight human subject, or an aging human subject. Preferably, a hormonally imbalanced human subject is selected from perimenopausal or postmenopausal women. Thermoregulation is important for bodily comfort and is beneficial for many other functional areas.

[0026] In a second preferred embodiment, regulating the autonomic nervous system in a human subject is to improve respiration and / or treat snoring. "Improving respiration" preferably includes one or more of reducing dyspnea, reducing shortness of breath, reducing chest tightness, and treating sleep apnea. More preferably, improving respiration includes one or more of reducing dyspnea, reducing shortness of breath, and reducing chest tightness.

[0027] Preferably, the composition is administered orally to human subjects.

[0028] The inventors have surprisingly discovered that administration of the composition within one hour before bedtime is preferable to produce the positive technical effects described herein on the modulation of the autonomic immune system. Preferably, the composition is administered to human subjects no later than 0.5 hours before bedtime, more preferably 0.5 to 1.5 hours before bedtime, and most preferably 0.75 to 1.25 hours before bedtime.

[0029] Preferably, the composition is administered to human subjects once a day.

[0030] Preferably, the composition is administered to human subjects over a period of at least 7 days, more preferably at least 14 days.

[0031] γ-aminobutyric acid The γ-aminobutyric acid (GABA) used herein is also known as 4-aminobutanoic acid and has CAS number 56-12-2.

[0032] Preferably, this composition provides a daily dose of γ-aminobutyric acid of 15 to 150 mg / day, more preferably 30 to 130 mg / day, and most preferably 45 to 120 mg / day.

[0033] Preferably, the amount of γ-aminobutyric acid in the composition is 100 to 1000 mg per 100 g dry weight of the composition, more preferably 150 to 800 mg per 100 g dry weight of the composition, and most preferably 200 to 600 mg per 100 g dry weight of the composition.

[0034] Jujube By adding jujube, a traditional plant-based food, this composition achieves not only physical and mental benefits but also economic and nutritional balance. Therefore, this composition is generally more tolerable and easier to use for consumers in Asia and China.

[0035] Preferably, jujube encompasses any part of the jujube plant (Ziziphus jujuba). More preferably, jujube is provided as jujube fruit, jujube leaves, jujube seeds, or a combination thereof. Even more preferably, jujube is provided as jujube seeds. Most preferably, jujube is provided as jujube seed powder.

[0036] Preferably, the weight ratio of γ-aminobutyric acid (mg) to jujube (mg) is in the range of 2:1 to 1:10, preferably 1:1 to 1:8, and more preferably 1:2 to 1:6.

[0037] Preferably, this composition provides a daily dose of jujube of 100 to 1000 mg / day, more preferably 150 to 800 mg / day, and most preferably 200 to 700 mg / day.

[0038] Preferably, the amount of jujube in the composition is 0.1 to 6 g per 100 g of dry weight composition, more preferably 0.3 to 5 g per 100 g of dry weight composition, and most preferably 0.5 to 4 g per 100 g of dry weight composition.

[0039] protein Preferably, the composition further contains protein.

[0040] Preferably, the weight ratio of γ-aminobutyric acid (mg) to protein (g) is in the range of 30:1 to 5:1, preferably 25:1 to 10:1.

[0041] Preferably, the composition provides a daily dose of protein of 3 to 9 g / day, more preferably 4.5 to 7.5 g / day, and most preferably 5.5 to 6.5 g / day.

[0042] Preferably, the amount of protein in the composition is 5 to 45 g per 100 g of dry weight composition, more preferably 15 to 35 g per 100 g of dry weight composition, and most preferably 20 to 30 g per 100 g of dry weight composition.

[0043] Preferably, the protein is milk protein. More preferably, the milk protein is whey protein, casein, or a combination thereof. The milk protein is preferably provided in any preferred form. For example, the milk protein may be provided by acidic whey, sweet whey, whey protein concentrate, whey protein isolate, casein salt, milk powder, skim milk powder, whole milk powder, or a combination thereof. Preferably, the milk protein is provided by whole milk powder.

[0044] Lipids Preferably, the composition further contains lipids.

[0045] Preferably, the composition provides a daily dose of lipids of 3 to 10 g / day, more preferably 5 to 8 g / day, and most preferably 6 to 7 g / day.

[0046] Preferably, the amount of lipids in the composition is 5 to 45 g per 100 g of dry weight composition, more preferably 15 to 35 g per 100 g of dry weight composition, and most preferably 20 to 30 g per 100 g of dry weight composition.

[0047] The lipids preferably contain polyunsaturated fatty acids (PUFAs). Preferably, the PUFAs contain omega-3 and / or omega-6 PUFAs. More preferably, the PUFAs contain one or more of docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), and docosapentaenoic acid (DPA). Even more preferably, the PUFAs contain DHA and / or EPA, and most preferably, the PUFAs contain both DHA and EPA.

[0048] Preferably, this composition provides a daily dose of DHA of 1 to 50 mg / day, more preferably 2 to 35 mg / day, and most preferably 5 to 15 mg / day.

[0049] Preferably, the amount of DHA in the composition is 4 to 200 mg per 100 g of dry weight composition, more preferably 8 to 140 mg per 100 g of dry weight composition, and most preferably 20 to 60 mg per 100 g of dry weight composition.

[0050] Preferably, this composition provides a daily dose of EPA of 1 to 50 mg / day, more preferably 3 to 35 mg / day, and most preferably 5 to 20 mg / day.

[0051] Preferably, the amount of EPA in the composition is 4 to 200 mg per 100 g of dry weight composition, more preferably 8 to 140 mg per 100 g of dry weight composition, and most preferably 20 to 80 mg per 100 g of dry weight composition.

[0052] Preferably, the weight ratio of DHA (mg) to EPA (mg) is in the range of 5:1 to 1:4, preferably 3:1 to 1:3, more preferably 2:1 to 1:2, and most preferably 1:1 to 1:1.5.

[0053] Preferably, the lipids include microbial oil, fish oil, milk fat, or a combination thereof.

[0054] The lipids preferably include fish oil and milk fat. Preferably, the weight ratio of fish oil (g) to milk fat (g) is in the range of 1:20 to 1:80, more preferably 1:30 to 1:70, and most preferably 1:40 to 1:60.

[0055] Preferably, the composition comprises fish oil containing 5 to 30 weight percent of EPA relative to the weight of fatty acids. More preferably, the composition comprises fish oil containing 10 to 25 weight percent of EPA relative to the weight of fatty acids.

[0056] Preferably, the amount of fish oil in the composition is 0.1 to 4 g per 100 g of dry weight composition, more preferably 0.2 to 3 g per 100 g of dry weight composition, and most preferably 0.2 to 2 g per 100 g of dry weight composition.

[0057] The milk fat is preferably provided as anhydrous milk fat, butter oil, butter fat, butter, whole milk powder, or a combination thereof. More preferably, the milk fat is provided by whole milk powder.

[0058] Preferably, the amount of milk fat in the composition is 5 to 45 g per 100 g of dry weight composition, more preferably 15 to 35 g per 100 g of dry weight composition, and most preferably 20 to 30 g per 100 g of dry weight composition.

[0059] Vitamins and minerals Preferably, the composition further contains vitamins.

[0060] Preferably, the vitamin is selected from folic acid, vitamin B6, vitamin B12, vitamin C, vitamin E, or a combination thereof.

[0061] Preferably, the composition provides a daily dose of folic acid of 10 to 300 μg / day, more preferably 50 to 250 μg / day, and most preferably 100 to 200 μg / day. Preferably, the amount of folic acid in the composition is 100 to 1200 μg per 100 g dry weight of the composition, more preferably 200 to 1000 μg per 100 g dry weight of the composition, and most preferably 400 to 700 μg per 100 g dry weight of the composition.

[0062] Preferably, the composition provides a daily dose of vitamin B6 of 100 to 600 μg / day, more preferably 200 to 500 μg / day, and most preferably 300 to 400 μg / day. Preferably, the amount of vitamin B6 in the composition is 0.1 to 20 mg per 100 g dry weight of the composition, more preferably 0.2 to 15 mg per 100 g dry weight of the composition, and most preferably 0.4 to 10 mg per 100 g dry weight of the composition.

[0063] Preferably, the composition provides a daily dose of vitamin B12 of 0.1 to 20 μg / day, more preferably 0.2 to 10 μg / day, and most preferably 0.4 to 5 μg / day. Preferably, the amount of vitamin B12 in the composition is 0.1 to 40 μg per 100 g dry weight of the composition, more preferably 0.2 to 20 μg per 100 g dry weight of the composition, and most preferably 0.4 to 10 μg per 100 g dry weight of the composition.

[0064] Preferably, the composition provides a daily dose of vitamin C of 1 to 100 mg / day, more preferably 5 to 75 mg / day, and most preferably 10 to 50 mg / day. Preferably, the amount of vitamin C in the composition is 10 to 300 mg per 100 g dry weight of the composition, more preferably 30 to 250 mg per 100 mg dry weight of the composition, and most preferably 50 to 200 mg per 100 g dry weight of the composition.

[0065] Preferably, the composition provides a daily dose of vitamin E of 0.1 to 20 mg α-TE / day (expressed as α-tocopherol equivalent [α-TE]), more preferably 0.5 to 15 mg α-TE / day, and most preferably 1 to 10 mg α-TE / day. Preferably, the amount of vitamin E is 1 to 200 mg α-TE per 100 g dry weight of the composition, more preferably 2 to 100 mg α-TE per 100 g dry weight of the composition, and most preferably 4 to 50 mg per 100 g dry weight of the composition.

[0066] Preferably, the composition further contains calcium. Preferably, the composition provides a daily dose of calcium of 50 to 500 mg / day, more preferably 100 to 400 mg / day, and most preferably 150 to 300 mg / day. Preferably, the amount of calcium in the composition is 400 to 1200 mg per 100 g dry weight of the composition, more preferably 600 to 1000 mg per 100 g dry weight of the composition, and most preferably 700 to 900 mg per 100 g dry weight of the composition.

[0067] composition The composition is preferably in the form of a supplement, a concentrated liquid, a ready-to-drink composition, or a powder. More preferably, the composition is a powder. Preferably, the powder is reconstituted with an aqueous liquid to prepare a liquid formulation, which is then administered orally to human subjects. Preferably, the aqueous liquid is water, more preferably warm water. Most preferably, the composition is a powder reconstituted with warm water.

[0068] Preferably, the compositions described herein are nutritional compositions.

[0069] Scoring method In a preferred embodiment, the use of a combination of γ-aminobutyric acid and jujube in the preparation of a composition for regulating the autonomic nervous system in a human subject is a scoring method for regulating the autonomic nervous system in a human subject, (i) γ-aminobutyric acid, (ii) Jujube The scoring method further comprises administering a composition containing the above to a human subject on a daily basis, the method being a. Steps to obtain user information from human subjects, b. A step to obtain a happiness level analysis by analyzing the obtained user information. c. Based on the results of the happiness analysis, • A step of providing a happiness score to human subjects, and / or • A step of providing one or more suggestions for behavioral change to human subjects. The process further includes applying a happiness scoring system, and steps a. to c. are repeated at least daily.

[0070] In an alternative preferred embodiment, the use of a combination of γ-aminobutyric acid and jujube in the manufacture of a composition for treating and / or preventing one or more stress, anxiety, depression and memory loss in human subjects is a scoring method for regulating the autonomic nervous system in human subjects, (i) γ-aminobutyric acid, (ii) Jujube The scoring method further comprises administering a composition containing the above to a human subject on a daily basis, the method being a. Steps to obtain user information from human subjects, b. A step to obtain a happiness level analysis by analyzing the obtained user information. c. Based on the results of the happiness analysis, • A step of providing a happiness score to human subjects, and / or • A step of providing one or more suggestions for behavioral change to human subjects. The process further includes applying a happiness scoring system, and steps a. to c. are repeated at least daily.

[0071] A third aspect of the present invention is a scoring method for regulating the autonomic nervous system in human subjects, (i) γ-aminobutyric acid, (ii) Jujube The method involves administering a composition containing the above to a human subject on a daily basis. a. Steps to obtain user information from human subjects, b. A step to obtain a happiness level analysis by analyzing the obtained user information. c. Based on the results of the happiness analysis, • A step of providing a happiness score to human subjects, and / or • A step of providing one or more suggestions for behavioral change to human subjects. The present invention further includes applying a happiness scoring system having a scoring method, wherein steps a. to c. are repeated at least daily.

[0072] The inventors have discovered that this scoring method can enhance and / or maintain the physical and mental state of human subjects, and thus enhance the positive effect of the claimed composition on regulating the autonomic nervous system, thereby enhancing the effect on the treatment and / or prevention of one or more of the following conditions in human subjects: hyperlipidemia, hypertension, diabetes, obesity / overweight, stress, anxiety, depression, and memory loss, preferably the effect on the treatment and / or prevention of one or more of the following conditions in human subjects:

[0073] Preferably, the happiness scoring system is a computer-implemented system, and preferably processed by a portable device.

[0074] As used herein, the term "happiness score" refers to a score, for example, on a scale of 1 to 10, that indicates the overall level of health of a subject. Preferably, a higher score indicates a higher level of happiness. The continuous adaptation of the happiness score in this scoring method provides feedback to the human subject on whether the intake of the composition and / or behavioral changes have resulted in an improvement in happiness. The happiness score may preferably be a perception of the user's behavior and may also be a psychological suggestion that enables the user to feel satisfied with their self-control and enter into a positive cycle of improved physical and mental health.

[0075] As used herein, the term "user information" refers to information relating to the behavior of human subjects and information relating to the characteristics of human subjects.

[0076] Examples of behavioral information for human subjects include one or more of the following: eating habits, sleeping habits, bowel movement patterns, menstrual cycle / pregnancy / lactation, exercise habits, meditation habits, etc.

[0077] Examples of information regarding the characteristics of a human subject include one or more pieces of information such as age, weight, height, sex, dietary restrictions, allergies, genetic information, family history, and location.

[0078] Preferably, all embodiments relating to the first and second aspects of the present invention are equally applicable to the third aspect of the present invention.

[0079] In this specification and the claims, the verb “includes” and its conjugations are used in a non-restrictive sense to mean that the items following the term are included, but not excluded, items not specifically mentioned. Furthermore, a reference to an element with the indefinite article “a” or “an” does not rule out the possibility of two or more of that element existing unless the context clearly requires that only one or one of those elements exist. Thus, the indefinite article “a” or “an” usually means “at least one.” [Examples]

[0080] Example 1 research participants Two hundred participants were selected from eight cities in China. These participants were aged 40–60 years, with a 1:1 ratio of participants over 50 to those under 50. The ratio of male to female participants was also 1:1. Female participants over 50 were either perimenopausal or menopausal. Participants were not diagnosed with any of the following conditions: severe mental or physical health problems, serious sleep problems, drug or alcohol abuse, diabetes, hypertension, or cardiovascular disease. Participants were neither allergic to dairy products nor lactose intolerant. Participants were not taking any sleep aids or sleep supplements.

[0081] methodology Study participants ingested the compositions listed in Table 1 daily for 14 consecutive days. These compositions were taken orally within one hour before bedtime. Participants completed an online questionnaire on the morning of day 0 (before ingestion), and on the mornings of days 7 and 14. In this questionnaire, participants rated their symptoms on a 5-point scale (1-5).

[0082] [Table 1]

[0083] result The results are reported in Tables 2-4.

[0084] [Table 2]

[0085] [Table 3]

[0086] [Table 4]

[0087] In summary, these results indicate improved regulation of the autonomic nervous system. In one aspect, the resulting regulation of the autonomic nervous system improved thermoregulation. As shown in Table 2, the improvement in thermoregulation was bidirectional (bidirectional is intended to encompass both raising and lowering body temperature). In another aspect, the improved regulation of the autonomic nervous system resulted in improved respiration and reduced snoring. In yet another aspect, improvements in depressed mood, anxious mood, tension, and memory loss are shown in Table 4.

Claims

1. A composition for regulating the autonomic nervous system in human subjects, further comprising milk protein, wherein the weight ratio of γ-aminobutyric acid (mg) to protein (g) is in the range of 30:1 to 5:1, in the production of the composition, (i) γ-aminobutyric acid, (ii) Natsume The use of a combination of these.

2. The use according to claim 1, wherein the composition is a nutritional composition.

3. The use according to claim 1 or 2, wherein regulating the autonomic nervous system improves thermoregulation.

4. The use according to claim 3, wherein improving thermoregulation means maintaining body temperature at approximately physiological body temperature.

5. The use according to claim 3 or 4, wherein the human subject is one or more of the following: a human subject with a disrupted hormone balance, a human subject receiving hormone therapy, a human subject with low body weight, a human subject with high body weight, or an aging human subject.

6. The use according to claim 5, wherein the human subject with a disrupted hormone balance is selected from perimenopausal women or menopausal women.

7. The use according to claim 1, wherein regulating the autonomic nervous system is to improve respiration and / or treat snoring.

8. The use according to any one of claims 1 to 7, wherein jujube is provided as an extract obtained from jujube fruit, jujube leaves, jujube seeds, or a combination thereof.

9. The use according to any one of claims 1 to 8, wherein the weight ratio of γ-aminobutyric acid (mg) to jujube (mg) is in the range of 2:1 to 1:

10.

10. The use according to any one of claims 1 to 9, wherein the amount of γ-aminobutyric acid is 100 to 1000 mg per 100 g dry weight of the composition.

11. The use according to any one of claims 1 to 10, wherein the amount of jujube is 0.1 to 6 g per 100 g of the dry weight of the composition.

12. The use according to any one of claims 1 to 11, wherein the composition comprises one or more of docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), and docosapentaenoic acid (DPA).

13. The use according to claim 12, wherein the weight ratio of DHA (mg) to EPA (mg) is in the range of 5:1 to 1:

4.

14. The use according to any one of claims 1 to 13, wherein the composition comprises one or more vitamins selected from folic acid, vitamin B6, vitamin B12, vitamin C, and vitamin E.

15. A scoring method for regulating the autonomic nervous system in human subjects, (i) γ-aminobutyric acid, (ii) Natsume The scoring method further comprises administering a composition containing the above to a human subject on a daily basis, the method being a. A step of obtaining user information from the aforementioned human subject, b. A step of analyzing the user information obtained above to obtain a happiness level analysis, c. Based on the results of the happiness analysis, - Providing a happiness score to the aforementioned human subject, and / or - A step of providing the aforementioned human subject with one or more suggestions for behavioral change. The use according to any one of claims 1 to 14 further comprises applying a happiness scoring system having, wherein steps a. to c. are repeated at least daily.

16. In the manufacture of a composition for treating and / or preventing one or more stress, anxiety, depression and memory loss in human subjects, (i) γ-aminobutyric acid, (ii) Natsume The use of a combination of these.

17. A scoring method for regulating the autonomic nervous system in human subjects, (i) γ-aminobutyric acid, (ii) Natsume The scoring method further comprises administering a composition containing the above to a human subject on a daily basis, the method being a. A step of obtaining user information from the aforementioned human subject, b. A step of analyzing the user information obtained above to obtain a happiness level analysis, c. Based on the results of the happiness analysis, - Providing a happiness score to the aforementioned human subject, and / or - A step of providing the aforementioned human subject with one or more suggestions for behavioral change. The use according to claim 16 further includes applying a happiness scoring system having, wherein steps a. to c. are repeated at least daily.

Images